Teva Pharmaceuticals (NASDAQ: TEVA)

polangevin

Ça fait un bout que je prêche en faveur de Teva. Voici les grandes lignes des résultats dévoilés ce matin:

Q4 2011 Highlights:

• 
  Net revenues of $5.7 billion, compared to $4.4 billion in the fourth
  quarter of 2010, an increase of 28%.
  
• 
  Non-GAAP net income and Non-GAAP EPS of $1.4 billion and $1.59 diluted
  earnings per share, an increase of 23% and 27%, respectively, compared
  to $1.1 billion and $1.25 diluted earnings per share in the fourth
  quarter of 2010.
  
• 
  Cash flow from operations of $1.4 billion, and free cash flow of $958
  million, an increase of 30% and 33%, respectively, compared to the
  fourth quarter of 2010.
  

2011 Highlights

• 
  Net revenues of $18.3 billion, compared to $16.1 billion in 2010, an
  increase of 14%.
  
• 
  Non-GAAP net income and Non-GAAP EPS of $4.4 billion and $4.97 diluted
  earnings per share, an increase of 7% and 9%, respectively, compared
  to $4.1 billion and $4.54 diluted earnings per share in 2010.
  
• 
  Cash flow from operations of $4.1 billion.